IP/Tech Buzz
Attorneys
Ryan C. Smith is a member of the Intellectual Property practice group at Larkin Hoffman Daly and Lindgren Ltd. Ryan focuses his practice on patent and technology issues for clients in the biomedical, chemical, pharmaceutical and medical device industries. Ryan’s background in pharmacology provides him with an in-depth understanding of drug, bio-affecting and body treating processes. He previously worked for the United States Patent and Trademark Office as a patent examiner, evaluating patent applications relating to drug delivery devices and pharmacology, as well as providing information regarding U.S. Patent Office policies to inventors. Bar Admissions Minnesota, May 2012 (expected) U.S. Patent and Trademark Office, 2011 Professional Associations & Memberships American Intellectual Property Law Association (AIPLA) Minnesota Intellectual Property Law Association (MIPLA) New York Academy of Sciences American Society for Pharmacology and Experimental Therapeutics (ASPET) Education William Mitchell College of Law, St. Paul, MN, J.D. 2010 Creighton University, Omaha, NE, Ph.D. 2007 Doctorate: Pharmacology Creighton University, Omaha, NE, B.S. 2000 Major: Biology
Service Areas
Intellectual Property, Technology and Internet |
1.JPG)
Update on the America Invents Act: Cost Considerations Associated with Post-Grant Review
The new Post-Grant Review (PGR) and Inter Partes Review (IPR) proceedings will broaden a third party’s ability to challenge patent validity. There seems to be a prevailing assumption that both proceedings will be significantly cheaper than bringing an action in district court. This assumption may not be true, however, given the fees associated with initiating a PGR or IPR proceeding.
Update on the America Invents Act: Virtual Marking
On September 16, 2011, President Obama signed the America Invents Act (“the Act”) into law. Included in the overhaul of Title 35 are significant changes to patent marking.
Update on the America Invents Act: Post-Grant Review
Ryan Smith discusses the latest developments in the America Invents Act (“AIA” or “the Act”). The Act is the largest overhaul of the United States patent system since 1952. Included in the overhaul are significant changes to the process for reviewing patents after issuance. The Act introduces two new proceedings for reviewing a granted patent – post-grant review and inter partes review
